Full-Time

Director of Learning and Development

EMD / Sleep

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$184k - $276k/yr

Pennsylvania, USA

Remote

Remote within Pennsylvania, with 30–40% travel required.

Bachelor's, Master's, MBA

Category
People & HR (1)
Required Skills
CRM
Data Analysis

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in business, healthcare, technology, or a related field is required.
  • At least 10 years of experience in learning and development, capability building, or commercial excellence within a pharmaceutical organization is required.
  • Six to eight years of experience leading people, including managing and developing high-performing teams and driving accountability across functions, is required.
  • Demonstrated experience leading teams that include Senior Managers, Associate Directors, or equivalent roles, with accountability for team performance, development, and outcomes, is required.
  • Deep understanding of learning and development, including adult learning principles, instructional design, and program development, with the ability to translate business needs into effective learning strategies and outcomes.
  • Strong judgment in balancing learning strategy, program design, and delivery realities to ensure training solutions are practical, scalable, and aligned with business priorities.
  • Proven ability to lead teams in developing and delivering learning programs across complex, cross-functional environments, including adapting content and delivery approaches to evolving business and field needs.
  • Experience leading and developing a high-performing team, including resource planning, performance management, and talent development.
  • Knowledge of CRM systems, data analytics, and digital tools used to enhance field-force effectiveness and data-driven decision-making.
  • Ability to develop training that helps field teams leverage insights and analytics for improved account planning and customer engagement.
  • Ability to mentor, coach, and elevate a high-performing team of five Senior Training Managers and one Associate Director of Learning and Development.
  • Ability to identify and leverage operational and strategic synergies across three distinct learning and development stakeholder types.
  • Ability to steward regulatory firewalls between Commercial and Medical Affairs learning and development initiatives and ensure compliance with corporate, legal, and regulatory guidelines.
  • Ability to collaborate across teams and reporting lines, coordinate shared work, and support decisions through professional alignment.
  • Ability to quickly absorb new insights and feedback, adapt approaches, and apply learning to practical situations.
  • Ability to understand upstream and downstream organizational effects, patterns, and interdependencies.
  • Ability to adopt new tools, ways of working, and behaviors with confidence.
  • Ability to improve processes and products through reflection and iteration.
  • Ability to travel 30% to 40%.
Responsibilities
  • Set direction for the Learning and Development team supporting Epilepsy/Movement Disorders and Sleep, ensuring objectives align with business priorities.
  • Translate business needs into team priorities, scope, and success measures by leading needs assessments and defining learning requirements.
  • Partner with franchise and functional leaders to translate disease strategies, launch priorities, and capability needs into role-based learning and prioritized training roadmaps.
  • Oversee the design, delivery, and facilitation of training programs and learning solutions, including onboarding, launch readiness, key account excellence initiatives, skill building, and mindset reinforcement.
  • Ensure the team delivers high-quality training with clear expectations for scope, timing, and outcomes.
  • Measure and monitor training effectiveness and use insights to improve programs.
  • Use stakeholder feedback to improve learning content development and delivery.
  • Build and lead a high-performing, scalable team by setting priorities, managing performance, and developing talent.
  • Serve as the senior customer-experience Learning and Development representative across Commercial, Medical, and Market Access stakeholders.
  • Represent the Epilepsy/Movement Disorders and Sleep Learning and Development team in cross-functional forums and team-level planning discussions.
  • Communicate franchise needs, dependencies, and constraints and reflect them in team priorities.
  • Oversee training development and implementation for CRM systems, data analytics, and digital tools.
  • Foster a culture of continuous improvement, psychological safety, and advanced adult-learning expertise.
  • Ensure cross-functional strategies and shared resources adhere to corporate compliance, legal, and regulatory guidelines.
Desired Qualifications
  • An advanced degree, such as an MBA or relevant graduate degree, is preferred.
  • Experience in healthcare, pharmaceutical, or other highly regulated industries is preferred.
  • Experience with rare disease or specialty brands and an understanding of unique stakeholder dynamics is preferred.
  • Experience in the Sleep and/or Epilepsy therapeutic areas is preferred.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $1.21 billion, and guidance rose to $4.75 billion.
  • Zepzelca grew 60% in Q1 2026 on first-line maintenance adoption.
  • Zanidatamab gained FDA Priority Review, positioning Jazz for a near-term oncology launch.

What critics are saying

  • Granules settlement allows a Xywav generic under certain conditions after March 2026.
  • Jazz still carries $4.35 billion debt, with $1.0 billion 2030 notes now exchangeable.
  • Zanidatamab faces an August 25, 2026 PDUFA; rejection cripples launch expectations.

What makes Jazz Pharmaceuticals unique

  • Xywav dominates narcolepsy and idiopathic hypersomnia through low-sodium oxybate differentiation.
  • Jazz owns scarce neurology and oncology assets, including Epidiolex, Zepzelca, and Ziihera.
  • Actio acquisition on August 10, 2026 extends its rare-epilepsy precision medicine franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.

Yahoo Finance
Aug 5th, 2026
Jazz Pharmaceuticals hits $1.2B quarterly revenue, raises full-year guidance to $4.75B on oncology surge

Jazz Pharmaceuticals reported record quarterly revenue of $1.2 billion for Q2 2026, marking a 16% year-over-year increase driven by double-digit growth across all key promoted brands. The oncology portfolio grew 32% year-over-year, supported by rapid adoption of Zepzelca in first-line maintenance and the successful launch of Modeyso. Xywav demonstrated 13% revenue growth as its low-sodium profile continues to differentiate it from high-sodium generics. The company raised its full-year revenue guidance to $4.60 billion–$4.75 billion. Jazz anticipates the 25 August PDUFA date for zanidatamab in first-line HER2-positive gastric cancers, with commercial teams prepared for immediate launch. The company is leveraging its biliary tract cancer infrastructure to support the zanidatamab rollout. Non-GAAP adjusted gross margin declined slightly due to higher sales mix of royalty-bearing products.

Yahoo Finance
Jun 23rd, 2026
Jazz Pharmaceuticals' lung cancer drug fails trial but investors spared as focus shifts to first-line treatment

Jazz Pharmaceuticals' phase 3 trial evaluating Zepzelca in second-line small-cell lung cancer failed to meet its primary endpoint of overall survival. However, the setback's impact may be limited as Zepzelca's commercial focus has already shifted. In 2025, the FDA granted full approval to Zepzelca combined with Roche's Tecentriq as a first-line maintenance treatment for extensive-stage small-cell lung cancer. That approval demonstrated a 46% reduction in disease progression risk and a 27% reduction in death risk compared with Tecentriq alone. Zepzelca sales increased 60% year over year to approximately $101 million in Q1 2026, driven by first-line maintenance adoption. The drug contributed only 7% of Jazz's total 2025 revenue of $4.3 billion, with neurological medications Xywav and Epidiolex generating significantly larger sales.